Noncanonical MAVS signaling restrains dendritic cell-driven antitumor immunity by inhibiting IL-12

Area of Science:

• Immunology
• Cancer Biology
• Cellular Signaling

Background:

• Mitochondrial antiviral signaling protein (MAVS)-mediated cytosolic RNA sensing is crucial for innate immunity and tumor immunogenicity.
• The precise role of host MAVS signaling in shaping antitumor immunity and its therapeutic implications remain incompletely understood.

Purpose of the Study:

• To elucidate the function of the host MAVS pathway in regulating antitumor immunity.
• To investigate the impact of MAVS deficiency in dendritic cells on anti-tumor CD8+ T cell responses.
• To explore the therapeutic potential of antagonizing MAVS signaling in dendritic cells for cancer immunotherapy.

Main Methods:

• Utilized genetic ablation models to investigate MAVS function in host cells, specifically dendritic cells (DCs).
• Assessed CD8+ T cell priming capacity and tumor-reactive T cell responses.
• Analyzed cytokine production (e.g., IL-12, IFN-γ) and signaling pathways (e.g., NF-κB).
• Evaluated tumor responses to immunotherapy and radiation therapy.

Main Results:

• Host MAVS signaling was found to support tumor growth and suppress antitumor immunity.
• MAVS deficiency in DCs enhanced tumor-reactive CD8+ T cell responses in an IL-12-dependent manner.
• Loss of the RIG-I/MAVS cascade activated the noncanonical NF-κB pathway, leading to increased IL-12 production by DCs.
• MAVS ablation sensitized tumors to immunotherapy and attenuated radiation resistance, improving effector CD8+ T cell maintenance.

Conclusions:

• The host MAVS pathway acts as a negative regulator of DC-driven antitumor immunity.
• Targeting MAVS signaling in DCs represents a promising strategy to enhance anti-tumor immunity and improve the efficacy of cancer immunotherapies.